Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Aclaris Therapeutics, Inc.

NASDAQ: ACRS · Life Sciences · 5 alerts · CIK 1557746

Aclaris Therapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$3.61Close, Nov 16
Market cap
$572M
Shares outstanding
158.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aclaris Therapeutics, Inc. filings on SEC EDGAR ↗

6:14 AM ET 8-K
Clinical Trial Data

Aclaris Therapeutics Clinical Trial Data

Aclaris Therapeutics announced that its Phase 2 ADMIRATION trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis failed to meet its primary and secondary endpoints. Despite robust target engagement and biomarker downregulation, the company will shift focus toward its oral ITK inhibitors and bispecific antibody ATI-052. The company also announced the initiation of a Phase 2b trial for modzatinib in lichen planus and plans to file an IND for ATI-9494 in Q4 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.